Max Financial: consolidated PAT up 37% YoY to ₹118 Cr as insurance segment profit jumps 40%
PAT +36.83% YoY · revenue +16.75% · margins expanding
₹14,969.51 Cr
+16.75% YoY
₹118.29 Cr
+36.83% YoY
0.79%
+0.1pp YoY
₹2.78
Max Financial Services' consolidated (primary basis) PAT came in at ₹118.29 Cr for Q1 FY27, up 36.8% year-on-year from ₹86.45 Cr, on revenue from operations of ₹14,969.51 Cr, up 16.8% YoY from ₹12,821.65 Cr. On a sequential basis the print is a turnaround from Q4 FY26's ₹31.52 Cr loss (revenue ₹10,801.94 Cr) — but that comparison is a seasonality/mark-to-market artifact rather than the headline story, since YoY is the primary read here and both periods were profitable. Net premium income from the life insurance business was ₹7,275.42 Cr, up 18.2% YoY (₹6,156.38 Cr), broadly consistent with management's own press release claiming 17% YoY growth in Individual Adjusted First Year Premium and an improved private market share of 10.1%.
Q1 FY-2027 vs prior quarters
The margin bridge sits mainly in investment/fair-value swings and the life insurance segment. Consolidated PBT was ₹137.92 Cr versus ₹101.48 Cr YoY (+35.9%) and versus a ₹38.07 Cr loss in Q4 FY26; net gain on fair value changes flipped from a ₹93.59 Cr loss last quarter to a ₹47.44 Cr gain this quarter (versus ₹35.57 Cr a year ago), and this line is the single biggest swing factor in the QoQ turnaround. Net profit margin improved to 0.79% of total income from 0.67% a year ago and from a negative 0.29% loss margin last quarter. By segment, Life Insurance (Axis Max Life) delivered a PBT of ₹168.24 Cr, up 40.3% YoY from ₹119.95 Cr and a swing from a ₹2.68 Cr segment loss in Q4 FY26; Business Investments stayed a small loss (₹1.89 Cr) roughly flat with the ₹2.04 Cr loss a year ago.
The stock went into the print at ₹1,512.4, down 6.1% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.
Management reinforces its FY26 Value of New Business (VNB) margin guidance of 24% to 25%, supported by stronger-than-expected sales outcomes and successful mitigation of GST impacts. The company is confident of continuing its strong, broad-based growth momentum, aiming to outpace the market by 300-500 basis points over
A web search for Street/consensus estimates on this print did not turn up an explicit PAT or revenue consensus figure — pre-result previews (e.g., niftytrader) instead flagged Value of New Business (VNB) margin and AUM growth as the metrics investors would watch, and this filing (financial statements plus notes only) does not disclose VNB margin, so that watch item remains unresolved pending the investor presentation/concall. On guidance, management's most recent stated target — a 24-25% VNB margin for FY26, reinforced in the February 2026 concall — was specific to the fiscal year that has since closed and is not directly re-tested by this Q1 FY27 filing; no fresh FY27 guidance appears in the statement itself, so this print cannot be graded against a live numeric target from this document alone. Corporate developments this quarter were largely non-P&L: the long-pending SEBI show-cause notice against the company and AMLI (over historical AMLI share transactions) remains open with no impact reflected in these results, a ₹4,720 penalty was levied for an NRC compliance lapse, and post-quarter-end the subsidiary received GST show-cause notices totaling ₹35.29 Cr (Aug 8) while redeeming a ₹496 Cr NCD tranche (Aug 4) and making a ₹5,329 Cr debenture payment (Aug 1); the proposed amalgamation of Axis Max Life and MFSL continues to progress through regulatory and shareholder approvals per the notes to accounts.
W1
VNB margin trajectory against management's 24-25% FY26 guidance — not disclosed in this filing; watch the investor presentation/concall for an FY27 reset
W2
Persistency ratios and new-business lapses, flagged as a pre-result watch item — not disclosed in this filing
W3
Resolution of the ₹35.29 Cr GST show-cause notices (received Aug 8, 2026) and the pending SEBI show-cause notice, both currently carrying no P&L impact
W4
Progress on the proposed Axis Max Life–MFSL amalgamation, pending further regulatory and shareholder approvals per the filing notes
Consolidated PAT of 118.29 Cr includes nil discontinued-ops contribution this quarter (vs +1.68 Cr in Q4 FY26); the PDF's raw text-extraction order scrambled the four period columns, so figures were column-locked using the structured table view cross-checked against the previous-quarter/year-ago figures supplied in context (exact match). Standalone Q4 FY26 PAT of 10.17 Cr included a one-off 14.02 Cr dividend from AMLI not repeated this quarter. No exceptional/one-off items flagged in the consolidated P&L notes for Q1 FY27 or Q1 FY26, so no adjusted-PAT computation applies.
Embedded Value Growth & Premium Momentum — What Q1 FY-27 Will Reveal
Max Financial Services reports Q1 FY-27 results on Aug 13. Expect continued traction on premium growth and embedded value accretion, but watch for any margin compression and guidance on full-year trajectory. Stock has pulled back 20% from ATH; FII buying has surged to 48%.
What Matters Most in Q1 FY-27
For Max Financial Services, the core question in Q1 is whether Axis Max Life's premium growth trajectory and embedded value accretion can hold momentum amid a softer equity market and potential headwinds on persistency. FY26 showed Individual Adjusted First Year Premium up 19% YoY and VNB growth of 26% — aggressive growth for a maturing insurance platform. Q1 FY-27 will test whether that pace is sustainable or a cyclical peak.
~₹9,200–9,500 Cr
On-plan: ~16–17% YoY growth; FY26 run-rate was ₹38,039 Cr annualized
~₹2,550–2,650 Cr
Extrapolating 19% YoY growth from FY26; watch for premium mix shift toward protection
Watch sequential growth
Mar-26 EV: ₹28,870.5 Cr; expect continued accretion from VNB gains and delta on new business
Watch for pressure
Key swing factor: June market volatility may have dented renewal ratios or elevated lapses in existing book
On Track? FY-26 Setup & Full-Year Guidance
Max Financial delivered 17% consolidated revenue growth and a 26% VNB lift in FY26, with embedded value expanding to ₹28,870.5 Cr. Management did not publicly issue a formal FY-27 guidance at the time of the FY-26 result (May 2026), so the Street is working from the trajectory: 15–17% top-line growth is viewed as on-plan; below 12% would signal deceleration. The absence of a full-year guidance in the latest filing means Q1 FY-27 could be the moment the board recalibrates expectations — watch for any commentary on persistency trends and the path to profitability in newer insurance verticals.
What the Street Says
Since Last Quarter (Q4 FY-26)
Max Financial has been active on capital management and regulatory front:
Reading into the filings: The ₹5,329 Cr debenture payment ahead of schedule is routine debt management and reflects confidence in liquidity. Axis Bank's ₹380.6 Cr equity injection into Axis Max Life (Jun) is bullish — it reinforces the parent's commitment to the insurance subsidiary's growth and suggests board-level confidence in premium trajectory. No insider selling or pledge activity flagged; promoter holding steady at ~1.25%. No red flags.
1 · Individual Adjusted First Year Premium (AFY) — growth rate & mix
FY26 saw 19% YoY growth to ~₹9,88 Cr. Q1 FY-27 expectations: 15–18% YoY. Any print below 12% would suggest market headwinds are biting harder than guided. Also watch: the split between protection (low-margin but stable) vs investment-linked policies (ILPs, higher margin but cyclical).
2 · Persistency ratios & new business lapses
Jun 2026 saw equity market volatility (Nifty fell ~8% from May high). Watch for any disclosure on 13-month, 25-month, or 37-month persistency — a tick down there signals value erosion and could cap upside guidance. This is the swing factor.
3 · Embedded Value (EV) accretion and guidance
Mar-26 EV stood at ₹28,870.5 Cr. Q1 accretion drivers: new business VNB, investment gains (unlikely in Q1, given volatility), and duration/delta effects. Expect management commentary on FY-27 EV guidance or medium-term target.
4 · Margin trajectory — cost of acquisition (CoA) & operating expense ratio (OER)
Insurance cycle: premium growth can mask rising unit costs (higher commissions, tech investment). Watch for any margin compression YoY. Strong Q1 is revenue growth + stable or expanding margins.
5 · FY-27 guidance — top-line, margin, and growth reset
Management may use the Aug 13 board meeting to issue or confirm FY-27 guidance. Absent formal guidance last time, the Street is hungry for this. Any guidance below 12–14% consolidated revenue growth would be a disappointment.
The Setup
Max Financial enters Q1 FY-27 as a re-rated stock — FII ownership nearly doubled in one year, yet the name trades 20% below ATH on a softer macro backdrop and absent full-year guidance. The embedded value moat (₹28,870.5 Cr, growing at 26% VNB CAGR) offsets maturity concerns, but execution risk is real: premium growth rates are cyclical, and a macro slowdown (slower credit growth, equity volatility) can deflate growth expectations quickly. Q1 results will settle two questions: (1) Can Axis Max Life hold mid-teens premium growth into the new fiscal year, or is FY26's 19% a cycle peak? (2) Are margins holding as the platform scales, or is rising CoA eating into profitability? A strong quarter (15%+ revenue growth, stable-to-higher margins, EV accretion >₹500 Cr sequential, and FY-27 guidance of 12–15% growth) re-rates the stock closer to fair value; a weak quarter (sub-12% growth or margin squeeze) could trigger a fresh sell-off into the AGM on Aug 19.
Max Financial Services reports Q1 FY-27 results on Aug 13 after market close. The core narrative: embedded value growth and premium momentum. Expect mid-teen revenue growth and 20%+ VNB lift on-plan; watch for any slide in persistency or margin pressure. FII inflows (up to 48%) suggest institutional confidence in the valuation, but DII outflow hints at domestic caution — result day will tell whether that divergence narrows or widens. Three things matter: (i) Individual AFY premium growth rate (below 12% = red flag), (ii) persistency disclosures (any tick down = value risk), (iii) FY-27 guidance (absence of it would be a disappointment). Stock is cheap on embedded value and priced for steady-state growth; upside requires proof of cycle sustainability.